Through analyzing TCGA dataset of HCC specimens and clinic information, we found STEAP4 level was reduced in patients with recurrence, suggesting STEAP4 might inhibit chemotherapy resistance, so we started to determine whether STEAP4 regulated cisplatin-induced chemotherapy resistance. This evidence concerns the gene STEAP4 and hepatocellular carcinoma.